Almirall SA · BME:ALM
Almirall SA — Merger or Acquisition (July 2007)
21 slides from Almirall SA's merger presentation, July 2007
Slide 1: Almirall
Zg . (& Almirall Solutions thinking of you
Slide 2: Introduction
Introduction 2
Slide 3: Background
Background Almirall recently completed its IPO and trading commenced on 20 June 2007 The strategy communicated at the time of IPO was to use the proceeds to fund business growth to 9 Increase international presence through partnerships and/or acquisitions 9 Leverage R&D pipeline Today, Almiral
Slide 4: Key Transaction Highlights
Key Transaction Highlights Hermal is the number 1 specialist prescription dermatology company in Germany with a leading position in the European dermatology market Hermal has 426 employees of which 11% are dedicated to R&D and 35% to sales & marketing Cash acquisition of 100% of Hermal from Re
Slide 5: Strategic Rationale
Strategic Rationale 1. Hermal is a solid and profitable business with strong track record of growth 2. Supports the build-up of a Pan-European presence and adds critical mass in Germany 3. Creates a leading dermatology/inflammatory indication platform, expands current product offering and allows for
Slide 6: 1. Hermal
1. Hermal 6
Slide 7: Overview of Hermal
Overview of Hermal Leading specialist prescription dermatology company in Europe Number 1 position in Germany Hermal has 426 employees and revenues of €102m in 2006 Strong brand and reputation amongst dermatology community Consistent detailing to specialist physicians Four core indicatio
Slide 8: Selected Key Products
Selected Key Products Product Comments Decoderm Number one GP dermatology product in Germany (Eczema) Unique first line treatment for inflamed and infected skin Balneum Europe’s number one medicated bath oil (Eczema) Hermal’s most well-known product Broad geographic reach Verrumal Europe
Slide 9: Key Financials
Key Financials Hermal Revenues (€m1) Comment 2 74 79 102 7.6% revenue CAGR (2004-2006) 100.0 (excluding contract manufacturing 17 CAGR 7.6 % sales to RB) 5 80.0 2 1 2006 EBITDA €22.6m 31 60.0 30 29 2006 EBITDA margin 22% (and 26% excluding contract manufacturing 40.0 sales to RB) 47 49 44 20
Slide 10: 2. Geographical expansion
2. Geographical expansion 10
Slide 11: Strong geographical fit
Strong geographical fit Adds critical mass in Germany Entry into UK and Eastern Europe Hermal direct presence Almirall direct presence Almirall presence through partnerships 11
Slide 12: Almirall continues its international expansion
Almirall continues its international expansion • Opening of French • Opening of • Subsidiary • Signing of • Acquisition of subsidiary Italian established Pantopan Sofotec (acquisition of subsidiary in Germany agreement for (Germany) Acquisition of French company Italy and • Forest Hermal Pharmafarm
Slide 13: 3. Dermatology
3. Dermatology 13
Slide 14: Attractions of Dermatology Market
Attractions of Dermatology Market Key strategic market for Almirall 9 One product for psoriasis in phase II and several other dermatological programmes in discovery feasibility Specialist pharma market implying 9 Lower cost of detailing due to focus on high prescribing specialists 9 Less severe
Slide 15: Leading position in Europe
Leading position in Europe Number 1 prescription dermatology company in Germany and among the leading European dermatology players Unique and respected heritage – a trusted partner to the dermatology community Broad product portfolio with a range of different formulations Strong “Hermal” umb
Slide 16: 4. Synergies
4. Synergies 16
Slide 17: Synergies
Synergies Optimisation of international network Complimentary geographical footprints Cross-selling opportunities Complementary product development and formulation expertise Positive tax impact of goodwill amortisation Fully implemented in 2 years 17
Slide 18: 5. Financial effects
5. Financial effects 18
Slide 19: Transaction Highlights
Transaction Highlights Key terms Cash acquisition of 100% stake of Hermal for an Enterprise Value of €3761m / £255m Acquisition financed through internal resources and external bank facilities Hermal will enter into a 3 year contract manufacturing agreement with Reckitt Beckinser as part of th
Slide 20: Conclusions
Conclusions 20
Slide 21: Conclusions
Conclusions Large step towards Pan European presence 9 Increases weight of International sales in Almirall portfolio 9 Strengthens position in attractive dermatology franchise 9 Adds specialty pharma expertise and marketing power 9 Complementary formulation and development expertise 9 Re